Web Exclusives

In the phase 2 OVARIO study, median progression-free survival has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities. Read Article ›

An all-oral regimen in women with recurrent platinum-sensitive ovarian cancer did not show superiority to platinum-based regimens on the outcome of progression-free survival. Read Article ›

In a meta-analysis of 7 large randomized clinical trials, PARP inhibitors were not significantly more likely to cause secondary hematologic malignancies compared with control groups. Read Article ›

A pooled analysis of 2 studies using rucaparib for the treatment of patients with recurrent high-grade ovarian cancer supported the approved starting dose of 600 mg twice daily. Read Article ›

A global phase 3 randomized study is currently enrolling patients with stage III or IV high-grade nonmucinous epithelial ovarian cancer to assess the efficacy of an investigational anti–PD-1 humanized monoclonal antibody plus standard of care as first-line treatment and maintenance. The primary outcome measure is progression-free survival. Read Article ›

It is a Herculean effort to develop a novel vaccine on an unprecedented timeline. Experts discuss the latest research regarding the development of vaccine candidates for the COVID-19 virus and some of the issues that will need to be addressed when a successful candidate has been identified, including clinical trial enrollment, manufacturing, and distribution. Read Article ›

Community oncology practices say they are recovering from the COVID-19 pandemic and keeping their eye on the goal of value-based care. The strategies they are using to accomplish these initiatives include innovation, long-term integration of telehealth, and the leveraging of advanced practice professionals. Read Article ›

The COVID-19 pandemic has created significant barriers to care, which can lead to increased mortality rates for thousands of patients with cancer. Nurses and nurse navigators are focused on using their skills and experience to combat this trend. Ongoing efforts include educating patients on the importance of undergoing cancer screenings, utilizing telehealth services to enhance communication with patients, addressing staffing shortages, and taking the necessary steps for preparing for potential spikes in COVID-19 cases. Read Article ›

Can the use of telehealth services help to address the upcoming burden of late cancer diagnoses, improve the co-management of chronic conditions, and give patients more power over their own health? During a recent AVBCC webinar, a panel of experts explored this question as they discussed the potential role of wearables, remote monitoring and communication, and other innovative technology for improving care for patients with cancer. Read Article ›

From the management of extended payment terms and performance-based agreements, to the potential impact of the proposed 2021 Medicare rules and the impending shortages of immune globulin, wholesale suppliers discuss how the COVID-19 pandemic continues to affect the oncology supply chain, what is being done to help practices, and what challenges lie ahead. Read Article ›

Although several of the financial indicators in oncology have recovered to pre-pandemic levels following dramatic declines that occurred earlier in the year, there are still significant challenges ahead. How will providers manage the backlog? What will happen to patients’ insurance coverage? How will oncology practices survive and thrive in a post–COVID-19 world? Read Article ›

Initiatives to expand patient access programs, strategies to secure the supply chain, and updates on vaccine trials: leaders from top pharmaceutical manufacturers discussed their companies’ ongoing response to the worldwide pandemic in this AVBCC webcast. Read Article ›

Page 10 of 20